Clinical Trial Update: Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring tislelizumab with neoadjuvant radiotherapy and chemotherapy for resectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Advanced Esophageal Squamous Cell Cancer | Phase 2 | Status: UNKNOWN